Invivyd, Inc. (NASDAQ:IVVD) Receives $7.33 Consensus PT from Analysts

Shares of Invivyd, Inc. (NASDAQ:IVVD) have received a consensus rating of “Hold” from the seven research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $8.00.

IVVD has been the subject of a number of recent research reports. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. BTIG Research initiated coverage on shares of Invivyd in a report on Monday. They set a “buy” rating and a $10.00 target price for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research report on Monday. D Boral Capital cut shares of Invivyd from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Finally, Zacks Research upgraded shares of Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th.

Invivyd Trading Down 1.4%

IVVD stock opened at $2.76 on Friday. The stock has a 50-day moving average price of $2.18 and a two-hundred day moving average price of $1.38. Invivyd has a 1 year low of $0.35 and a 1 year high of $3.07. The stock has a market cap of $643.41 million, a PE ratio of -5.87 and a beta of 0.61.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $13.13 million during the quarter, compared to the consensus estimate of $12.00 million. Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%. On average, analysts forecast that Invivyd will post -1.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Kevin F. Mclaughlin purchased 50,000 shares of the firm’s stock in a transaction on Wednesday, November 19th. The stock was purchased at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the purchase, the director directly owned 50,000 shares in the company, valued at $125,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 25.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Invivyd

Several hedge funds and other institutional investors have recently made changes to their positions in IVVD. Catalyst Funds Management Pty Ltd bought a new stake in Invivyd during the second quarter worth $27,000. Vanguard Personalized Indexing Management LLC increased its stake in shares of Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after purchasing an additional 28,146 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Invivyd by 330.5% during the 3rd quarter. Bank of America Corp DE now owns 49,252 shares of the company’s stock worth $54,000 after purchasing an additional 37,811 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of Invivyd in the 3rd quarter valued at about $102,000. Finally, Bridgeway Capital Management LLC acquired a new stake in Invivyd in the 3rd quarter valued at about $109,000. 70.36% of the stock is owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.